Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Ghrelin
Also known as: GHRL, lenomorelin, hunger hormone
Over 10,000 published studies on PubMed. That puts ghrelin among the most researched peptide hormones in endocrinology. This 28-amino-acid molecule, discovered in 1999, is the only known circulating hormone that tells your brain to eat. It also triggers growth hormone release through the GHS-R1a receptor. The catch: native acylated ghrelin degrades in under 13 minutes after IV administration. Plasma esterases strip the octanoyl modification almost immediately. In an 8-week cancer cachexia trial, daily subcutaneous ghrelin at 13 mcg/kg raised appetite and slowed fat loss (Lundholm et al.)[1]. Most people chasing ghrelin receptor effects turn to GHRP-2, GHRP-6, or MK-677 instead.
What Is Ghrelin?
Twenty-eight amino acids with a fatty acid tail that breaks every rule. Ghrelin (CAS 258279-04-8) was identified in 1999 by Kojima and colleagues as the endogenous ligand for the growth hormone secretagogue receptor GHS-R1a [2]. The octanoyl group attached to Ser3 by ghrelin O-acyltransferase (GOAT) is what makes the molecule bind its receptor. Without that lipid tag, ghrelin is biologically inactive at GHS-R1a.
The stomach produces ghrelin in gastric oxyntic cells. Levels rise before meals and fall after eating. When ghrelin reaches the hypothalamus, it activates NPY/AgRP neurons and suppresses the satiety pathway (POMC/CART signaling). The result is a strong hunger signal. At the pituitary, it triggers growth hormone release through a calcium-dependent pathway independent of GHRH. That dual action, appetite plus GH secretion, made it a therapeutic candidate for cancer cachexia and wasting diseases.
Clinical data partly backs this up. Lundholm and colleagues gave weight-losing cancer patients once-daily subcutaneous ghrelin at 13 mcg/kg or 0.7 mcg/kg for 8 weeks. The high dose raised appetite scores and reduced loss of whole-body fat versus the low dose [1]. A 2013 clinical review of human ghrelin studies found that ghrelin infusions and boluses consistently raised appetite or food intake across multiple populations (PMC3644599). The GHS-R1a target is so validated that anamorelin, a synthetic ghrelin receptor agonist, received approval in Japan for cancer cachexia and completed Phase 3 trials globally (eClinicalMedicine 2025).
The practical problem is pharmacokinetic. Active acylated ghrelin survives 9 to 13 minutes in plasma after IV dosing. Even subcutaneous delivery extends this to only 30 to 60 minutes. Native ghrelin isn't sold as a consumer peptide. Lab-grade material, sold only as a reagent for research, runs $253 or more per milligram.
How Ghrelin Works
Ghrelin's biological activity starts at the GHS-R1a receptor, a G-protein-coupled receptor expressed in the anterior pituitary, arcuate nucleus, vagal afferents, and throughout the gastrointestinal tract. The receptor requires ghrelin's octanoyl modification at Ser3 for activation; des-acyl ghrelin does not bind.
At the pituitary, GHS-R1a activates Gq/11-mediated signaling. Intracellular calcium rises. Growth hormone releases into circulation, independent of the GHRH pathway. Giving ghrelin and GHRH together produces a larger GH peak than either alone (PMID 11238504 (opens in a new tab)). Researchers proposed this combined response as a provocation test for GH deficiency (PMID 11549707 (opens in a new tab)).
The appetite arm runs through the hypothalamus. Ghrelin activates NPY/AgRP neurons in the arcuate nucleus while simultaneously inhibiting POMC/CART neurons. The net signal is hunger, peaking 30 to 60 minutes after administration. No other peripheral hormone does this; leptin, GLP-1, and PYY all suppress appetite.
One detail separates ghrelin from every other peptide hormone. The GOAT enzyme attaches a medium-chain fatty acid (octanoyl, C8) to serine-3. Without this modification, the peptide cannot bind GHS-R1a. Des-acyl ghrelin circulates at 3 to 4 times the concentration of the active form but has zero receptor activity at the target.
In the gut, ghrelin activates vagal afferents to speed gastric emptying and increase acid secretion. Peripheral tissues respond through AMPK-dependent signaling, shifting metabolism toward fatty acid oxidation and glucose sparing.
Ghrelin Benefits
- Ghrelin benefits center on appetite restoration, GH release, and metabolic support in catabolic states.
- Reliable GH release via GHS-R1a activation. In a placebo-controlled trial in healthy young men, IV bolus doses of 1 and 5 mcg/kg raised mean peak GH to 124 and 153 ng/mL within 90 minutes [3].
- Weight-losing cancer patients on 13 mcg/kg/day subcutaneous ghrelin for 8 weeks had higher appetite scores and lost less body fat than patients on 0.7 mcg/kg/day (Lundholm et al.)[1].
- Gastroprokinetic effects speed gastric emptying through vagal afferent activation. Direct therapeutic relevance for gastroparesis and functional dyspepsia populations.
- Cardioprotective signaling through AMPK-dependent pathways has been mapped in preclinical cardiac injury models, with reduced infarct size and improved left ventricular function.
- Neuroprotection data from animal models shows reduced neuronal apoptosis in ischemia. Human translation is still early, but the preclinical signal is consistent across multiple research groups.
- The anamorelin Phase 3 trial in gastric cancer confirmed the GHS-R1a target works therapeutically. Japan granted approval for cancer cachexia based on this data (eClinicalMedicine 2025).
Ghrelin: Science vs Community Consensus
Native acylated ghrelin is effective for appetite stimulation in catabolic/wasting populations (cancer cachexia, COPD, heart failure) and reliably triggers GH pulses in clinical GH stimulation testing.
Read the evidence (key study, limitations)
All clinical dosing is weight-based (mcg/kg). Practical use is limited by extreme half-life instability (~9-13 min for active acyl-ghrelin IV). Ghrelin receptor agonists (anamorelin) have advanced to Phase 3 / Japan approval for cancer cachexia, underscoring validated therapeutic relevance of the GHS-R1a target.
Lundholm et al. (Cancer 2010): SC ghrelin 13 vs 0.7 mcg/kg/day for 8 weeks in weight-losing cancer patients; high dose raised appetite and reduced fat loss; PMID 20186829. Neary et al. (JCEM 2004): one IV ghrelin infusion raised buffet energy intake 31% in 7 cancer patients; PMID 15181065. PMC3644599 clinical review of human ghrelin administration. Anamorelin Phase 3 gastric cancer RCT (eClinicalMedicine 2025).
Active acyl-ghrelin half-life only 9–13 min IV; no validated SC bioavailability measurement in humans. All clinical protocols are IV or weight-based SC: fixed-dose consumer-style tiers are not clinically derived. Native ghrelin is unavailable through consumer peptide channels. Cancer risk through GHS-R1a on tumor cell lines is clinically documented.
Native ghrelin has near-zero community self-administration.
Read the reports (what users report 2, common issues 4)
The research peptide community uses synthetic GHS-R1a agonists (GHRP-2, GHRP-6, ipamorelin, MK-677) exclusively. Native acylated ghrelin is not sold in the consumer research-peptide market. Community familiarity is primarily informational: "hunger hormone" educational interest.
- Concept validates GHS-R1a agonist class (GHRP-2, GHRP-6, ipamorelin)
- Academic understanding of hunger regulation
- Not sold as a research-grade consumer peptide
- Active form degrades in ~10 min: impractical for self-administration
- Research-grade lab pricing (~$253+/mg)
- All clinical dosing is weight-based; no fixed-dose protocol exists
Science has extensive data (10,000+ PubMed papers, multiple Phase 2/3 trials); community does not use native ghrelin at all: synthetic GHS-R1a agonists serve the same receptor target with practical pharmacokinetics.
Ghrelin Dosage Guide
Native ghrelin is a lab chemical, not a consumer peptide. It isn't part of the usual research-grade market. It is sold only as a lab reagent for research, at $253+ per milligram. That price is telling you something about the practical reality of this compound.
For the 5 mg vial at 2 mL bacteriostatic water: each 0.1 mL (10 units on an insulin syringe) delivers 250 mcg. A 50 mcg beginner dose is 2 units. A 100 mcg moderate dose is 4 units.
The thing most people miss: acylated ghrelin is not the same as des-acyl ghrelin. The octanoyl group at Ser3 is what makes it active at GHS-R1a. Your certificate of analysis must specify which form you have. Temperature sensitivity is extreme; keep this frozen at -20C until reconstitution. After mixing, use within 2 weeks refrigerated.
If you want GHS-R1a receptor effects with practical pharmacokinetics, GHRP-2 (100 mcg SC, 2 to 3 times daily), GHRP-6 (100 to 200 mcg SC before meals), or MK-677 (25 mg oral daily) are the community-tested alternatives. Dose on an empty stomach; food blunts the GH response.
Cycling Protocol
Due to potential GHS-R1a desensitization with chronic exposure, cycling is recommended. Clinical research protocols typically use acute or short-term dosing. Monitor appetite, weight, and fasting glucose during on periods.
Chronic continuous GHS-R1a stimulation leads to receptor tachyphylaxis: reduced GH-releasing and appetite-stimulating response over time. Clinical cachexia protocols typically use 4–12 week defined courses rather than indefinite continuous use. A 4-week off-break allows receptor resensitization. No published cycling data exists specifically for native ghrelin; recommendation is extrapolated from GHRP class receptor pharmacology and the 8/4 cycling pattern used in community GHS-R agonist protocols.
- Reduced appetite stimulation compared to first 2 weeks
- Declining GH pulse magnitude on consistent dosing
- Plateaued or reversed weight trajectory despite continued dosing
- Worsening insulin resistance without dose change
Or use the universal Peptide Calculator for any peptide.
Ghrelin Protocols by Goal
Expected: Higher appetite scores and less loss of whole-body fat at 13 mcg/kg/day than at 0.7 mcg/kg/day over 8 weeks (Lundholm 2010, PMID 20186829). Serum IGF-1 did not differ between doses.
Monitor: Fasting blood glucose before and weekly during treatment. Body weight and food intake log. IGF-1 at 4 weeks if prolonged course.
How to Use Ghrelin
- 1Remove the lyophilized ghrelin vial from -20C storage
Allow it to reach refrigerator temperature (2 to 8C) before reconstitution. Do not leave at room temperature.
- 2Draw 2 mL of bacteriostatic water into a syringe
Direct the stream along the inside wall of the vial. Swirl gently until dissolved. Do not shake.
- 3Step 3
Concentration after reconstitution: 5 mg in 2 mL = 2,500 mcg per mL. Each unit on a U-100 insulin syringe (0.01 mL) = 25 mcg.
- 4For a 50 mcg dose (beginner tier): draw to the 2-unit mark
For 100 mcg (moderate): 4 units. For 200 mcg (aggressive): 8 units. Clinical weight-based dosing at 1 mcg/kg for a 70 kg person is 70 mcg, which is approximately 2.8 units.
- 5Clean the injection site with an alcohol swab
Pinch skin at the abdomen or thigh. Insert a 29 to 31 gauge needle at a 45-degree angle subcutaneously. Inject slowly. Hold 5 seconds before withdrawing.
- 6Step 6
Rotate injection sites with each administration.
- 7Step 7
Timing: for appetite stimulation, inject 30 to 60 minutes before the main meal. For GH release, inject on an empty stomach (minimum 2 hours fasted, 4 hours preferred), ideally morning or before sleep.
- 8Store reconstituted vial at 2 to 8C
Use within 2 weeks. For best acyl-ghrelin retention, use within 24 hours of mixing.
Alternative Routes
1–5 mcg/kg single bolus for GH stimulation testing
Gold standard for GH stimulation tests and PK studies. Fastest onset (GH peak 15–30 min). Acyl-ghrelin t½ ~9–13 min IV. Requires IV access and clinical monitoring. Not suitable for self-administration.
Rate-controlled to maintain target ghrelin plasma levels; varies by study protocol
Used in PK characterization and metabolic studies. Sustains active ghrelin levels but requires hospital setting. Rebounding GH/insulin/glucagon after infusion cessation is a known clinical concern.
0.7 or 13 mcg/kg/day SC for cachexia (Lundholm 2010); ~1 mcg/kg for appetite studies
Active ghrelin peak at ~30 min SC. SC bioavailability not formally measured in humans: estimated but unconfirmed. Most practical route outside IV setting. Rapid des-acylation by plasma esterases reduces active fraction significantly.
N/A: peptide degraded by GI proteases and nasal mucosal enzymes
Oral route not viable for native ghrelin. Non-peptide GHS-R1a agonist MK-677 (ibutamoren) was developed specifically to achieve oral bioavailability of ghrelin receptor activation.
Ghrelin Stacking Protocols
Works With
Synthetic GHS-R1a agonist that mimics ghrelin's GH-releasing effects with practical pharmacokinetics (t½ ~1h). Community-preferred alternative to native ghrelin for GH release.
100 mcg SC 2–3x daily on empty stomach
Synthetic GHS-R1a agonist; similar mechanism to native ghrelin with stronger appetite drive than GHRP-2. Preclinical and community evidence for GH/appetite effects.
100–200 mcg SC 2–3x daily before meals
Selective GHRP with minimal cortisol/prolactin stimulation compared to native ghrelin. Often paired with CJC-1295 for GH optimization in community protocols.
Oral non-peptide GHS-R1a agonist: the most practical route to sustained ghrelin receptor activation. Eliminates injection issues and half-life degradation problems of native ghrelin.
25 mg oral daily before bed
Avoid
Directly opposes ghrelin-mediated GH release at the pituitary. Somatostatin analogs (octreotide, lanreotide) are functional antagonists: co-administration eliminates ghrelin's GH-releasing effect entirely.
Do not combineOpposing appetite effects: GLP-1RAs suppress hunger while ghrelin stimulates it. Co-administration creates pharmacological conflict and negates ghrelin's orexigenic indication.
Ghrelin raises blood glucose via GH-mediated insulin resistance and direct hepatic effects. Dose adjustment of diabetes medications required if co-administered; increased monitoring mandatory.
Both ghrelin and glucocorticoids raise blood glucose via separate mechanisms: additive hyperglycemia risk is clinically documented.
Estimated Cost
Ghrelin Side Effects
The most serious safety concern with ghrelin is the cancer risk. GHS-R1a and GHS-R1b receptors are expressed on multiple cancer cell lines. Acylated ghrelin activates PI3K/Akt proliferative signaling and has been shown to induce cisplatin resistance in some tumor models. Any active or suspected malignancy is a hard contraindication. The irony is that cancer cachexia is ghrelin's primary therapeutic indication. That creates genuine clinical tension requiring oncologist involvement for any use.
Blood glucose elevation is the second major concern. Ghrelin raises glucose through two mechanisms: GH-mediated insulin resistance and direct hepatic glucose output. Clinical trial participants required weekly fasting glucose monitoring. If fasting glucose exceeds 126 mg/dL without pre-existing diabetes, discontinuation is the recommended response. Pre-diabetic individuals and anyone on insulin or oral hypoglycemics need dose adjustments and closer monitoring. Corticosteroid co-administration compounds this risk through separate hyperglycemic pathways.
Appetite stimulation itself is a safety issue in specific populations. Prader-Willi syndrome patients already have pathologically raised endogenous ghrelin driving extreme hyperphagia. Researchers are actually working on GOAT inhibitors to block ghrelin's effects in PWS. Active eating disorders (binge eating disorder, bulimia) are absolute contraindications.
Common side effects from clinical trials include increased hunger (expected and dose-dependent), transient flushing within the first 30 minutes, mild nausea, and diarrhea. Raised gastric acid secretion has been reported. A 2013 review of 121 human studies counted adverse effects in the 66 studies that reported them: about 20% of those 939 participants had mild ones, mostly flushing and stomach rumbling (PMID 23533240 (opens in a new tab)). In an 8-week trial of daily injections, serum IGF-1 did not differ between 13 and 0.7 mcg/kg, and the authors saw no adverse effects of the high dose, tumor markers included [1].
Injection site reactions (redness, swelling) occur with subcutaneous administration, consistent with other injectable peptides.
No safety data exists for ghrelin use during pregnancy or breastfeeding. This is an absolute contraindication.
The pharmacokinetic profile creates its own practical safety issue. Active acylated ghrelin degrades in 9 to 13 minutes IV, roughly 30 minutes subcutaneously. Temperature excursions during storage destroy bioactivity. Material from outside laboratory channels should be treated as unverifiable. Lab-grade product requires validated cold-chain handling and costs $253+ per milligram.
Drug interactions need specific attention. Insulin and oral hypoglycemics may need dose adjustment. Somatostatin analogs (octreotide, lanreotide) directly block ghrelin's GH-releasing effect. GLP-1 receptor agonists (semaglutide, liraglutide) create pharmacological conflict by suppressing the appetite ghrelin is trying to stimulate. Exogenous growth hormone adds to IGF-1 elevation risk. Corticosteroids compound the hyperglycemia problem.
When to stop: fasting glucose above 180 mg/dL unresponsive to management, any new cancer diagnosis, weight gain goal reached, or beyond 12 weeks of continuous use (long-term safety data past this point is limited). When to see a doctor: persistent hyperglycemia, signs of new mass or unexplained weight changes, or any allergic reaction at the injection site.
Common Issues & Solutions
Reduced appetite stimulation after week 4–6: likely GHS-R1a tachyphylaxis: cycle off for 4 weeks and reassess. Do not escalate dose without clinical guidance.
Elevated fasting glucose (>100 mg/dL): reduce dose or increase dose interval; add glucose monitoring. Discontinue if fasting glucose exceeds 126 mg/dL without pre-existing diabetes.
Inconsistent GH response: ensure fasting state (≥2h minimum, ≥4h preferred) before injection; food consumption significantly blunts ghrelin-mediated GH release.
Degraded peptide / no effect: native acylated ghrelin degrades within minutes at room temperature and requires -20°C storage. Verify vial has been kept frozen. Acylated form is unstable: even brief temperature excursions destroy bioactivity.
Water retention / edema: the 2013 review of 121 human ghrelin studies names mild flushing and stomach rumbling as the main side effects, not swelling (PMID 23533240 (opens in a new tab)), and serum IGF-1 did not rise with dose in the 8-week trial [1]. New or worsening swelling needs a doctor, not a dose change.
Ask AI about this page
Ask AI for a second opinion on Ghrelin dosing and side effects
Contraindications
- Active malignancy: ghrelin may promote tumor growth through GHS-R1a expressed on some cancer cell lines
- Uncontrolled diabetes mellitus: ghrelin raises blood glucose via GH-mediated insulin resistance and direct hepatic effects
- Pregnancy or breastfeeding: no safety data available in these populations
- Prader-Willi syndrome: already characterized by elevated ghrelin and hyperphagia
- Active eating disorders (binge eating disorder, bulimia): appetite stimulation is contraindicated
- Known hypersensitivity to ghrelin or any excipients
Drug Interactions
- Insulin and oral hypoglycemics: ghrelin increases blood glucose; may require dose adjustment of diabetes medications
- Exogenous growth hormone: additive GH elevation; increased risk of IGF-1-related side effects
- Somatostatin analogs (octreotide, lanreotide): directly oppose ghrelin-mediated GH release; reduced efficacy
- GLP-1 receptor agonists (semaglutide, liraglutide): opposing appetite effects may negate ghrelin's orexigenic action
- Corticosteroids: both ghrelin and glucocorticoids raise blood glucose; additive hyperglycemia risk
- Atropine and anticholinergics: may blunt ghrelin's gastroprokinetic effects
Product Quality
Native acylated ghrelin is not sold in the consumer research-peptide market. It is sold only as a lab reagent for in vitro / animal research, at research-grade pricing ($253+/mg). The critical acylation at Ser3 (octanoyl group) required for bioactivity is chemically fragile and temperature-sensitive: even properly sourced material requires validated cold-chain handling. There is no consumer-facing quality standard or certificate of analysis framework applicable here. Ghrelin from any non-laboratory channel should be treated as extremely high-risk.
- Lab-grade ghrelin comes with published purity certificates (≥95% HPLC purity)
- Verify acylated vs. des-acyl form: des-octanoyl ghrelin is biologically inactive at GHS-R1a; this distinction must be confirmed on the COA
- Maintain -20°C cold chain from receipt through use; even brief temperature excursions degrade acylated form
- Reconstitute in cold PBS or sterile water; use within 24 hours for maximum acyl-ghrelin retention
- Native ghrelin sold as a consumer peptide should be treated as unverifiable; use synthetic GHS-R1a agonists (GHRP-2, ipamorelin) as validated practical alternatives
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Fasting blood glucose | Baseline, then weekly during active dosing | <100 mg/dL fasting; >126 mg/dL warrants dose reduction or discontinuation |
| IGF-1 | Baseline, then at 4 weeks for courses ≥4 weeks | Age/sex-adjusted reference; avoid supraphysiologic elevation |
| Body weight and food intake log | Daily during active protocol | Not listed |
| HbA1c | Baseline and at 8–12 weeks for extended courses or in pre-diabetic individuals | <5.7%; higher risk monitoring threshold at ≥6.0% |
Ghrelin raises blood glucose via GH-mediated insulin resistance and direct hepatic glucose output; clinically documented in trial populations
Sustained GH stimulation elevates IGF-1; relevant for dose safety and efficacy confirmation
Primary efficacy endpoint in cachexia indication; tracks appetite response and weight trajectory
Chronic GH elevation induces long-term insulin resistance accumulation
Ghrelin Before and After
Rapid increase in circulating GH levels within 15-30 minutes. Noticeable hunger and appetite stimulation within 30-60 minutes. Possible mild flushing. Effects wane within 2-3 hours due to short half-life.
Consistent appetite increase when dosed pre-meal. GH pulses become more predictable. Some users report improved sleep quality. Possible mild water retention and increased food intake.
Improved gastric emptying rates. Serum IGF-1 did not differ between doses in the 8-week cachexia trial (PMID 20186829).
In an 8-week cancer cachexia trial, 13 mcg/kg/day raised appetite scores and reduced body fat loss versus 0.7 mcg/kg/day (PMID 20186829). Some GHS-R1a tachyphylaxis may begin to appear.
Receptor desensitization may reduce GH-releasing efficacy. Cycling off for 4 weeks is recommended to restore sensitivity. Appetite effects may partially persist. Long-term safety data beyond 12 weeks is limited.
What to Expect
First dose (0 to 2 hours): GH spikes within 15 to 30 minutes. Hunger hits at the 30 to 60 minute mark. You might notice mild flushing. Active ghrelin clears plasma fast, 9 to 13 minutes IV, roughly 30 minutes subcutaneously. Effects taper within 2 to 3 hours. No community self-administration data exists for native ghrelin; GHRP-2 users report comparable hunger onset at 20 to 30 minutes through the same receptor.
Days 1 to 7: Appetite increases become consistent when dosing before meals. GH pulses settle into a predictable pattern. Check fasting glucose at day 7.
Weeks 2 to 4: Gastric emptying rates improve (the gastroprokinetic effect). Serum IGF-1 did not differ between doses in the 8-week cachexia trial [1]. Pre-diabetic individuals should be watching fasting glucose closely here.
Weeks 4 to 8: In the 8-week cachexia trial, the high dose raised appetite and slowed body fat loss versus the low dose [1]. Some GHS-R1a tachyphylaxis may appear; the appetite effect tends to persist more than the GH response.
Weeks 8 and beyond: Receptor desensitization is expected with continuous use past 8 weeks. GH-releasing efficacy drops more than appetite effects. Glucose intolerance may accumulate progressively. A 4-week off-period is the standard recommendation to restore sensitivity. Long-term safety data beyond 12 weeks is limited across all published protocols.
Detailed Timeline: Science vs Community
GH peaks within 15–30 min of IV or SC administration. Active ghrelin (acyl form) clears plasma in 9–13 min IV / ~30 min SC. Appetite stimulation onset within 30–60 min. Transient mild flushing possible.
Not applicable: native ghrelin not community-used. GHRP-2 (equivalent receptor effect): users report hunger surge within 20–30 min, mild flushing, occasional warmth.
Consistent appetite increase when dosed pre-meal. GH pulses reproducible. Mild water retention possible.
N/A (see GHRP-2/GHRP-6 for community-equivalent timeline)
Improved gastric emptying (gastroprokinetic effect). Serum IGF-1 did not differ between doses in the 8-week cachexia trial (PMID 20186829).
N/A
Cachexia trial (Lundholm 2010, 8 weeks): 13 mcg/kg/day raised appetite scores and reduced body fat loss versus 0.7 mcg/kg/day. Some GHS-R1a tachyphylaxis may emerge.
N/A
GHS-R1a tachyphylaxis expected with continuous daily use beyond 8 weeks. Efficacy reduction for GH-releasing endpoint more pronounced than for appetite endpoint. Glucose intolerance may accumulate.
N/A
Pharmacokinetics
Source: Acyl-ghrelin plasma t1/2 9-13 min (PMID 15080773); SC half-life estimated at 60-90 min based on acyl-ghrelin clearance kinetics
Pharmacokinetics: Active Dose Over Time
t½ = ~9-13 minutes (IV, active acyl-ghrelin); ~30-60 minutes (SC)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Ghrelin Legal?
Ghrelin has no FDA approval for any therapeutic indication. Its regulatory status is research-only. Native acylated ghrelin is not sold as a consumer peptide. It is sold only as a lab reagent for in vitro and animal research purposes.
Anamorelin, a synthetic oral ghrelin receptor agonist, received approval in Japan for cancer cachexia in 2021. No equivalent approval exists in the United States or European Union for native ghrelin or any oral GHS-R1a agonist.
WADA prohibits all growth hormone secretagogues under section S2 of the prohibited list. This includes native ghrelin and synthetic GHS-R1a agonists (GHRP-2, GHRP-6, MK-677). Athletes subject to anti-doping testing should be aware that ghrelin and its metabolites are detectable.
This content is for educational and research purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any research compound. Ghrelin use outside of approved clinical research protocols is at the individual's own risk.
Evidence grade: Phase 3 trial (Peptide Evidence Gap, October 2026)
Who Should Consider Ghrelin
- Adults with cancer-related cachexia or anorexia seeking appetite restoration
- Patients with functional dyspepsia or gastroparesis requiring prokinetic support
- Elderly individuals with sarcopenia or age-related appetite decline
- Adults with growth hormone deficiency being evaluated with GH stimulation testing
- Researchers studying energy homeostasis, reward signaling, or GH secretion
Related Peptides
What Changed for Ghrelin
- Safety
Corrected Oct 18, 2026: ghrelin's side effects no longer blame edema on raised IGF-1; IGF-1 did not differ by dose over 8 weeks, per PubMed (PMID 20186829).
Before: Water retention and mild edema appeared in some study participants, related to sustained IGF-1 elevation from repeated GH pulses After: A review of 121 human studies: mild adverse effects in about 20% of the 939 participants with reported data, mostly flushing and stomach rumbling; in the 8-week trial, serum IGF-1 did not differ between 13 and 0.7 mcg/kg
What this does not mean: No new safety finding. A 2013 review of 121 human studies found mild adverse effects in about 20% of the 939 participants whose 66 studies reported them, mostly flushing and stomach rumbling (PMID 23533240).
Source: Cancer 2010, Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study (Lundholm et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Peptide Schedule Research TeamReviewed Apr 7, 202611 Citations
References
- [1]Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study (Cancer 2010) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Ghrelin is a growth-hormone-releasing acylated peptide from stomach (Nature 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects (Eur J Endocrinol 2004) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans (Endocrinology 2000) (opens in a new tab)PubMed 11089560PubMed
- Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice (Proc Natl Acad Sci 2010) (opens in a new tab)PubMed 20231469PubMed
- Ghrelin: structure and function (Physiol Rev 2005) (opens in a new tab)PubMed 15788704Review
- Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial (J Clin Endocrinol Metab 2004) (opens in a new tab)PubMed 15181065PubMed
- Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone (J Clin Endocrinol Metab 2001) (opens in a new tab)PubMed 11238504PubMed
- A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans (J Clin Endocrinol Metab 2001) (opens in a new tab)PubMed 11549707PubMed
- Clinical review: The human experience with ghrelin administration (J Clin Endocrinol Metab 2013) (opens in a new tab)PubMed 23533240Review
- Ghrelin and Cancer: Examining the Roles of the Ghrelin Axis in Tumor Growth and Progression (Biomolecules 2022) (opens in a new tab)PubMed 35454071Review
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Ghrelin?
Niche. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: Few. Community mentions on Reddit: Near zero for native ghrelin; GHS-R agonists (GHRP-2, MK-677.
10,000 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.